Human antibodies against amyloid β peptide:: A potential treatment for Alzheimer's disease

被引：148

作者：

Dodel, R

Hampel, H

Depboylu, C

Lin, SZ

Gao, F

Shock, S

Jäckel, S

Wei, W

Buerger, K

Höft, C

Hemmer, B

Möller, HJ

Farlow, M

Oertel, WH

Sommer, N

Du, YS

机构：

[1] Univ Marburg, Dept Neurol, D-35039 Marburg, Germany

[2] Univ Munich, Geriatr Psychiat Brand & Alzheimer Mem Ctr, Dementia Res Sect, Munich, Germany

[3] Univ Munich, Geriatr Psychiat Brand & Alzheimer Mem Ctr, Memory Clin, Munich, Germany

[4] Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA

来源：

ANNALS OF NEUROLOGY | 2002年 / 52卷 / 02期

关键词：

D O I：

10.1002/ana.10253

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Naturally occurring antibodies directed against beta-amyloid (Abeta) were detected in intravenous immunoglobulin preparations. After intravenous immunoglobulin treatment in patients with different neurological diseases, total Abeta and Abeta(1-42) in the cerebrospinal fluid was reduced significantly compared with baseline values. In the serum, total Abeta levels increased after intravenous immunoglobulin treatment, whereas no significant change was observed in Abeta(1-42) levels. Antibodies against Abeta were found to be increased in the serum and cerebrospinal fluid after intravenous immunoglobulin treatment. This study provides evidence that intravenous immunoglobulin or purified Abeta antibodies may modify Abeta and Abeta(1-42) levels, suggesting potential utility as a therapy for Alzheimer disease.

引用

页码：253 / 256

页数：4

共 21 条

[1]

ARMITAGE P, 1994, STAT METHODS MED RES, P389

[2] Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].

Bard, F ;

Cannon, C ;

Barbour, R ;

Burke, RL ;

Games, D ;

Grajeda, H ;

Guido, T ;

Hu, K ;

Huang, JP ;

Johnson-Wood, K ;

Khan, K ;

Kholodenko, D ;

Lee, M ;

Lieberburg, I ;

Motter, R ;

Nguyen, M ;

Soriano, F ;

Vasquez, N ;

Weiss, K ;

Welch, B ;

Seubert, P ;

Schenk, D ;

Yednock, T .

NATURE MEDICINE, 2000, 6 (08) :916-919

[3]

Bril V, 1999, CAN J NEUROL SCI, V26, P139

[4] Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease [J].

DeMattos, RB ;

Bales, KR ;

Cummins, DJ ;

Dodart, JC ;

Paul, SM ;

Holtzman, DM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (15) :8850-8855

[5] Reduced levels of amyloid β-peptide antibody in Alzheimer disease [J].

Du, Y ;

Dodel, R ;

Hampel, H ;

Buerger, K ;

Lin, S ;

Eastwood, B ;

Bales, K ;

Gao, F ;

Moeller, HJ ;

Oertel, W ;

Farlow, M ;

Paul, S .

NEUROLOGY, 2001, 57 (05) :801-805

[6] ALZHEIMER-TYPE NEUROPATHOLOGY IN TRANSGENIC MICE OVEREXPRESSING V717F BETA-AMYLOID PRECURSOR PROTEIN [J].

GAMES, D ;

ADAMS, D ;

ALESSANDRINI, R ;

BARBOUR, R ;

BERTHELETTE, P ;

BLACKWELL, C ;

CARR, T ;

CLEMENS, J ;

DONALDSON, T ;

GILLESPIE, F ;

GUIDO, T ;

HAGOPIAN, S ;

JOHNSONWOOD, K ;

KHAN, K ;

LEE, M ;

LEIBOWITZ, P ;

LIEBERBURG, I ;

LITTLE, S ;

MASLIAH, E ;

MCCONLOGUE, L ;

MONTOYAZAVALA, M ;

MUCKE, L ;

PAGANINI, L ;

PENNIMAN, E ;

POWER, M ;

SCHENK, D ;

SEUBERT, P ;

SNYDER, B ;

SORIANO, F ;

TAN, H ;

VITALE, J ;

WADSWORTH, S ;

WOLOZIN, B ;

ZHAO, J .

NATURE, 1995, 373 (6514) :523-527

[7] HUMAN-ANTIBODIES REACTIVE WITH BETA-AMYLOID PROTEIN IN ALZHEIMERS-DISEASE [J].

GASKIN, F ;

FINLEY, J ;

FANG, Q ;

XU, SH ;

FU, SM .

JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (04) :1181-1186

[8]

Ghersi-Egea JF, 2001, MICROSC RES TECHNIQ, V52, P83, DOI 10.1002/1097-0029(20010101)52:1<83::AID-JEMT10>3.0.CO

[9]

2-N

[10] AMYLOID DEPOSITION AS THE CENTRAL EVENT IN THE ETIOLOGY OF ALZHEIMERS-DISEASE [J].

HARDY, J ;

ALLSOP, D .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1991, 12 (10) :383-388

← 1 2 3 →